Mulai
CrashWhen

EBS: It's pretty bad when you underperform TNXP

Pembelian
Emergent Biosolutions, Inc. (NYSE:EBS)  
CrashWhen Diupdate   
NYSE:EBS   Emergent Biosolutions, Inc.
Trend Analysis Fundamental Analysis Beyond Technical Analysis
0
0
trendanalysis fundamental beyondta
Considering TNXP does... well... nothing, EBS underperforming TNXP is disappointing. Still holding and will continue to buy shares if SP falls back into the gray area at $25-$32. Monthly hammer + continuation off a high volume node + 2.618 fib should indicate a trend reversal.
EBS was never a "squeeze" play because it's already worth a billion dollars. Additionally, I don't believe monkey pox is a serious pandemic regardless of what WHO says. EBS still has a pipeline of drugs that generates revenue and profit. With or without Monkey Pox, EBS should see $50-$60 (fibs) imo.
Komentar:
Terrible miss on earnings with lowered guidance. More accumulation here.
Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.